Haemonetics says CSL Plasma expects U.S. rollout of its devices at all centers by end-2027

• Haemonetics disclosed an update on its non-exclusive U.S. supply agreement with CSL Plasma for NexSys PCS devices with Persona PLUS.
• CSL expects to complete the rollout by end-2027, targeting a transition across all current U.S. plasma collection centers.
• The rollout scope and timing remain subject to change under the agreement, with implementation details still being determined.
• No change to fiscal 2027 guidance; an impact update is planned for the November 2026 second-quarter earnings call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000313143-26-000138), on October 08, 2026, and is solely responsible for the information contained therein.